Monte Rosa Therapeutics Partners with Johnson & Johnson for Phase 2 Trial of MRT-2359 in Prostate Cancer
Event summary
- Monte Rosa Therapeutics has entered a clinical supply agreement with Johnson & Johnson to evaluate MRT-2359 in combination with ERLEADA® (apalutamide) for treating metastatic castration-resistant prostate cancer (mCRPC) with androgen receptor (AR) mutations.
- The Phase 2 trial, expected to start in Q3 2026, will assess the efficacy and safety of the combination in up to 25 mCRPC patients with AR mutations.
- MRT-2359 is an investigational, orally bioavailable, GSPT1-directed molecular glue degrader that has shown promising clinical activity in combination with AR inhibition.
- Monte Rosa will conduct and sponsor the trial, while Johnson & Johnson will provide ERLEADA® as part of the supply agreement.
The big picture
Monte Rosa Therapeutics is advancing its molecular glue degrader platform with a strategic partnership aimed at validating MRT-2359 in a high-unmet-need indication. The collaboration with Johnson & Johnson underscores the potential of combining novel degraders with established AR inhibitors to address treatment-resistant prostate cancer. Success in this trial could position Monte Rosa as a key player in the evolving landscape of targeted oncology therapies.
What we're watching
- Clinical Trial Progress
- The pace at which the Phase 2 trial initiates and enrolls patients will determine the timeline for generating critical efficacy and safety data.
- Regulatory Pathway
- Whether the data from this trial can position MRT-2359 for advancement into registrational studies, potentially accelerating its path to market.
- Competitive Landscape
- How Monte Rosa's molecular glue degrader technology differentiates itself in the crowded prostate cancer treatment space.
Related topics